SINTILIMAB for Hepatocellular carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 70 adverse event reports in the FDA FAERS database where SINTILIMAB was used for Hepatocellular carcinoma.
Most Reported Side Effects for SINTILIMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Myelosuppression | 127 | 19.5% | 2 | 63 |
| Nausea | 77 | 11.8% | 4 | 8 |
| Rash | 72 | 11.0% | 6 | 12 |
| Vomiting | 68 | 10.4% | 3 | 8 |
| Off label use | 64 | 9.8% | 13 | 29 |
| Hypothyroidism | 62 | 9.5% | 3 | 2 |
| Diarrhoea | 61 | 9.4% | 3 | 7 |
| Fatigue | 60 | 9.2% | 4 | 3 |
| Anaemia | 59 | 9.1% | 2 | 7 |
| Pyrexia | 51 | 7.8% | 1 | 15 |
| Therapy partial responder | 51 | 7.8% | 1 | 0 |
| Thrombocytopenia | 51 | 7.8% | 3 | 3 |
| Hypertension | 48 | 7.4% | 2 | 1 |
| Leukopenia | 45 | 6.9% | 1 | 1 |
| Neutropenia | 45 | 6.9% | 2 | 6 |
Other Indications for SINTILIMAB
Gastric cancer (91)
Lung neoplasm malignant (33)
Colorectal cancer metastatic (30)
Hepatic cancer (24)
Lung adenocarcinoma (19)
Tumour thrombosis (19)
Adenocarcinoma gastric (18)
Non-small cell lung cancer (18)
Lung squamous cell carcinoma stage iii (15)
Chemotherapy (14)
Other Drugs Used for Hepatocellular carcinoma
ATEZOLIZUMAB (8,443)
BEVACIZUMAB (7,773)
LENVATINIB (5,384)
SORAFENIB (4,986)
CABOZANTINIB S-MALATE (2,670)
DURVALUMAB (1,255)
NIVOLUMAB (1,142)
REGORAFENIB (1,050)
TREMELIMUMAB\TREMELIMUMAB-ACTL (589)
PEMBROLIZUMAB (518)